Abstract
This work describes a novel mechanism of neuroprotection by simvastatin: the modulation of seladin-1, an enzyme involved in Alzheimer's disease. Genomic and proteomic studies in human neuronal cells showed seladin-1 production to be increased in a dose- and time-dependent manner by simvastatin. This was confirmed in mice by immunohistochemical and qRT-PCR studies.